Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status Prescription; Discontinued
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 22365-121; 51927-0168; 66039-829; 0395-8244; 0093-3133; 63629-8818; 64552-4008; 62147-0087; 51672-4145; 99207-270; 62350-0077; 99207-276; 68462-536; 62147-0072; 45802-368; 68682-272; 99207-260; 72189-084; 71052-160; 99207-271; 0168-0432; 51552-1538; 58175-0397; 11517-270; 72643-006; 11517-275; 51927-4898; 51672-4174; 11517-262
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin ulcer24.04.03.007; 23.07.03.0030.009269%
Somnolence19.02.05.003; 17.02.04.006--
Squamous cell carcinoma16.16.01.002--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.0200.003476%
Supraventricular tachycardia02.03.03.012--
Swelling08.01.03.015--Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.0080.002317%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.003476%Not Available
Tachycardia02.03.02.007--Not Available
Tearfulness19.15.02.005--Not Available
Telangiectasia24.03.03.003; 23.06.03.0010.002317%
Tenderness08.01.08.005--Not Available
Teratogenicity12.03.01.032; 03.02.01.004--Not Available
Thinking abnormal19.10.03.001; 17.02.05.0230.002317%Not Available
Thrombocytopenia01.08.01.0020.003476%Not Available
Thyroiditis05.02.04.001--Not Available
Tinea cruris11.03.08.001; 23.09.02.003--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.005793%
Tooth disorder07.09.05.001--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.000907%
Ulcer08.03.06.0010.002317%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Uterovaginal prolapse21.07.05.001--Not Available
Vaginal discharge21.08.02.0020.002317%
Vaginal infection11.01.10.002; 21.14.02.002--
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 12 Pages